MX2016017388A - Metodos para tratar o aliviar la migraña. - Google Patents
Metodos para tratar o aliviar la migraña.Info
- Publication number
- MX2016017388A MX2016017388A MX2016017388A MX2016017388A MX2016017388A MX 2016017388 A MX2016017388 A MX 2016017388A MX 2016017388 A MX2016017388 A MX 2016017388A MX 2016017388 A MX2016017388 A MX 2016017388A MX 2016017388 A MX2016017388 A MX 2016017388A
- Authority
- MX
- Mexico
- Prior art keywords
- migraine
- methods
- treating
- administering
- partial agonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
En ciertas modalidades, la invención se refiere a métodos para tratar la migraña (por ejemplo, migraña episódica, migraña crónica, migraña retiniana, migraña oftalmopléjica, migraña acefálica, trastorno migrañoso, migraña menstrual, migraña abdominal, síndromes periódicos infantiles o cefalea en racimos) al administrar un péptido con agonista parcial de NMDAR. En ciertas modalidades, la invención también se refiere a métodos para tratar o aliviar las secuelas posteriores a la migraña a largo plazo en un paciente al administrar un péptido con agonista parcial de NMDAR. En otras ciertas modalidades, la invención se refiere a métodos para tratar, suprimir o prevenir la depresión de extensión cortical o una enfermedad o padecimiento causado por depresión de extensión cortical en un paciente en necesidad del mismo, que comprende administrar un péptido con agonista parcial de NMDAR. Por ejemplo, en la presente se proporcionan métodos para tratar epilepsia, lesión cerebral traumática y/o derrame cerebral.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462015727P | 2014-06-23 | 2014-06-23 | |
| US201562109386P | 2015-01-29 | 2015-01-29 | |
| PCT/US2015/037177 WO2015200322A1 (en) | 2014-06-23 | 2015-06-23 | Methods of treating or ameliorating migraine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016017388A true MX2016017388A (es) | 2018-02-19 |
Family
ID=54938737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016017388A MX2016017388A (es) | 2014-06-23 | 2015-06-23 | Metodos para tratar o aliviar la migraña. |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP3157943A4 (es) |
| JP (2) | JP6688748B2 (es) |
| KR (1) | KR20170018072A (es) |
| CN (1) | CN106661085A (es) |
| AU (1) | AU2015280108B2 (es) |
| BR (1) | BR112016030375A8 (es) |
| CA (1) | CA2953170A1 (es) |
| MX (1) | MX2016017388A (es) |
| RU (1) | RU2721401C2 (es) |
| WO (1) | WO2015200322A1 (es) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995006468A1 (en) * | 1993-09-01 | 1995-03-09 | Smithkline Beecham Corporation | Method for treating migraine headaches |
| DE60131033T2 (de) * | 2000-08-25 | 2008-07-17 | Research Corp. Technologies, Inc., Tucson | Verwendungen von antikonvulsiven Aminosäure zur Behandlung bipolarer Erkrankungen |
| EP1337559A2 (en) * | 2000-11-17 | 2003-08-27 | Bayer Ag | Regulation of human nmda receptor |
| ES2381091T3 (es) * | 2003-03-06 | 2012-05-23 | Botulinum Toxin Research Associates, Inc. | Tratamiento del dolor facial crónico y cefalea relacionados con la sinusitis con toxina botulínica |
| WO2010010908A1 (ja) * | 2008-07-23 | 2010-01-28 | 協和発酵キリン株式会社 | 片頭痛治療剤 |
| WO2011003064A2 (en) * | 2009-07-02 | 2011-01-06 | Naurex, Inc. | Methods of treating neuropathic pain |
| PL2985032T3 (pl) * | 2009-10-05 | 2019-07-31 | Northwestern University | Glyx do stosowania do leczenia choroby alzheimera, choroby parkinsona lub choroby huntingtona |
| US8951968B2 (en) * | 2009-10-05 | 2015-02-10 | Northwestern University | Methods of treating depression and other related diseases |
| BR112012020142A2 (pt) * | 2010-02-11 | 2020-08-18 | Northwestern University | moduladores do receptor de nmda com estrutura secundária estabilizada e usos dos mesmos. |
| EA201790653A1 (ru) * | 2011-04-27 | 2017-07-31 | Нортвестерн Юниверсити | Способ лечения болезни альцгеймера и других расстройств |
| WO2014059326A2 (en) * | 2012-10-12 | 2014-04-17 | Northwestern University | Methods of identifying compounds for treating depression and other related diseases |
-
2015
- 2015-06-23 CN CN201580033913.6A patent/CN106661085A/zh active Pending
- 2015-06-23 CA CA2953170A patent/CA2953170A1/en not_active Abandoned
- 2015-06-23 WO PCT/US2015/037177 patent/WO2015200322A1/en active Application Filing
- 2015-06-23 EP EP15811633.5A patent/EP3157943A4/en not_active Withdrawn
- 2015-06-23 MX MX2016017388A patent/MX2016017388A/es unknown
- 2015-06-23 JP JP2016575106A patent/JP6688748B2/ja active Active
- 2015-06-23 BR BR112016030375A patent/BR112016030375A8/pt not_active IP Right Cessation
- 2015-06-23 RU RU2017101410A patent/RU2721401C2/ru active
- 2015-06-23 KR KR1020177001848A patent/KR20170018072A/ko not_active Application Discontinuation
- 2015-06-23 AU AU2015280108A patent/AU2015280108B2/en not_active Ceased
-
2020
- 2020-04-06 JP JP2020068289A patent/JP2020114863A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112016030375A8 (pt) | 2021-07-13 |
| EP3157943A1 (en) | 2017-04-26 |
| CA2953170A1 (en) | 2015-12-30 |
| CN106661085A (zh) | 2017-05-10 |
| RU2721401C2 (ru) | 2020-05-19 |
| RU2017101410A (ru) | 2018-07-24 |
| KR20170018072A (ko) | 2017-02-15 |
| AU2015280108B2 (en) | 2019-11-28 |
| JP2017519778A (ja) | 2017-07-20 |
| JP6688748B2 (ja) | 2020-04-28 |
| EP3157943A4 (en) | 2018-01-24 |
| AU2015280108A1 (en) | 2017-01-19 |
| JP2020114863A (ja) | 2020-07-30 |
| RU2017101410A3 (es) | 2019-01-21 |
| BR112016030375A2 (pt) | 2017-08-15 |
| WO2015200322A1 (en) | 2015-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018002990A (es) | Uso de la akkermansia pasteurizada para tratar trastornos metabolicos. | |
| MX2016000364A (es) | Metodos para tratar o prevenir afecciones oftalmologicas. | |
| MX2021008113A (es) | Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma. | |
| PH12016501966B1 (en) | Compounds and compositions as toll-like receptor 7 agonists | |
| DOP2017000268A (es) | Metodos y kits para tratar depresion | |
| GB2541571A (en) | Pharmaceutical compositions | |
| MX2015015249A (es) | Peptidos terapeuticos. | |
| PH12019501018A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
| MX2016005446A (es) | Intervenciones a base de angiopoyetina para tratar la malaria cerebral. | |
| PH12016500140A1 (en) | Heterobicycloaryl rorc2 inhibitors and methods of use thereof | |
| MX2017006437A (es) | Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor. | |
| EA201691020A1 (ru) | Способы лечения и предотвращения вызываемой аллогенными антителами хронической болезни "трансплантат против хозяина" | |
| EA201691567A1 (ru) | Способы лечения легких травм головного мозга | |
| CO2020005485A2 (es) | Administración oral de análogos del péptido glp-1 | |
| MX2015010296A (es) | Tratamiento de formas progresivas de esclerosis multiple con laquinimod. | |
| MX2017010654A (es) | Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres. | |
| UA118474C2 (uk) | (s)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині | |
| MX2018002298A (es) | Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos. | |
| MX2017013879A (es) | Composiciones que comprenden anakinra. | |
| MX2016014740A (es) | Un metodo para el tratamiento de trastornos del movimiento con befiradol. | |
| MX2019014090A (es) | Métodos para el tratamiento de la reservoritis crónica. | |
| PH12018500682A1 (en) | Oxa-diazaspiro compounds having activity against pain | |
| MX2016017388A (es) | Metodos para tratar o aliviar la migraña. | |
| MX2018004532A (es) | Combinacion de trazodona y gabapentina para el tratamiento de dolor. | |
| GB201115977D0 (en) | Neurodevelopmental disorders |